


# Normalizing tumor blood vessels may improve immunotherapy against brain cancer

March 13 2023, by Noah Brown



Anti-VEGF treatment improves the efficacy of EGFRvIII-CAR-T cells in murine GBM tumor models. (A) Schematic representation of experimental setup to evaluate the effect of PBS, CAR-T, B20, IgG+CAR T and B20+CAR T on the survival of GSC005 and C2TA GBM-bearing mice. (B) and (C) Tumor

growth kinetics and median survival for CT2A tumors (PBS (n=22, 15.5 days), CAR-T (n=14, 20.5 days), B20 (n=8, 24.5 days), B20+CAR T (n=19, 32 days)). (D) and (E) Tumor growth kinetics and median survival for GSC005 tumors (PBS (n=12, 13.5 days), CAR-T (n=17, 18.5 days), B20 (n=10, 24 days), IgG+CAR T (n=13, 18 days), B20+CAR T (n=21, 37 days)). Error bars show median $\pm$ SEM. Statistical analysis was performed using Student's t-test or one-way ANOVA test. \*p

Citation: Normalizing tumor blood vessels may improve immunotherapy against brain cancer (2023, March 13) retrieved 24 May 2024 from <https://medicalxpress.com/news/2023-03-tumor-blood-vessels-immunotherapy-brain.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.